This week Bayer announced the launch of Calantic Digital Solutions, a suite of applications intended to optimize clinical workflows by triaging and prioritizing critical findings, improving disease detection and automating tasks for radiologists.
PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam.
Members who signed the letter were particularly critical of the fact that the shortage is a result of COVID lockdowns in China, stating that this crisis brings to light “the urgent need to establish an outbound investment review process to ensure that critical capabilities are not being offshored ..."